Alzheimer's Disease Therapeutics Market size to grow by USD 5.41 billion from 2023-2028; North America to account for 39% of market growth - Technavio
NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The Alzheimer's disease therapeutics market size is expected to grow by USD 5.41 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 10.03% during the forecast period, according to Technavio Research. The market is segmented based on Distribution Channel (Hospital Pharmacy, Retail pharmacy, and E-commerce pharmacy), Drug Class (Cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 39% to the growth of the global market during the forecast period. Factors such as the increasing awareness of the disease and its strong prevalence of Alzheimer's disease drive regional market growth during the forecast period. The prevalence of the disease has been increasing at a significant rate in developed countries in North America. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a FREE PDF Sample Report
Company Profile:
AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd.
AB Science SA: The company offers Alzheimer's disease therapeutics such as Masitinib.
To gain access to more vendor profiles available with Technavio, buy the report!
Alzheimer's Disease Therapeutics Market: Segmentation Analysis
By distribution channel, the market growth in the hospital pharmacy segment will be significant over the forecast period. The segment is driven by the rapid growth in the number of hospitals in developing countries such as India and the rise in government initiatives to develop healthcare infrastructure. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2018 to 2022"- Technavio
Alzheimer's Disease Therapeutics Market: Driver & Trend:
Driver
- Availability, research, and development of novel biomarkers
- Increasing awareness of Alzheimer's disease
- Strong pipeline coupled with approval of therapeutics
The availability, research, and development of novel biomarkers drive market growth. The prevalence of Alzheimer's disease has increased globally, thus, developing new therapies to treat patients with Alzheimer's disease has become critically important.
Increasing funding for therapeutic discovery is an emerging market trend. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information.
Related Reports:
The global neuromuscular disease therapeutics market size is estimated to grow by USD 6,513.28 million at a CAGR of 10.3% between 2022 and 2027.
The Global Addiction Therapeutics Market size is estimated to grow at a CAGR of 7.65% between 2022 and 2027. The addiction therapeutics market size is forecast to increase by USD 9.86 billion.
What are the key data covered in this Alzheimer's disease therapeutics market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the Alzheimer's disease therapeutics market between 2023 and 2028.
- Precise estimation of the Alzheimer's disease therapeutics market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the Alzheimer's disease therapeutics across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of Alzheimer's disease therapeutics market vendors.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Distribution Channel
Market Segmentation by Drug Class
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article